GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Price-to-Free-Cash-Flow

Atara Biotherapeutics (Atara Biotherapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-27), Atara Biotherapeutics's share price is $0.69. Atara Biotherapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83. Hence, Atara Biotherapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Atara Biotherapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

ATRA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.52
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Atara Biotherapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.47. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.83.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 9.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.30% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -8.00% per year.

During the past 12 years, Atara Biotherapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 20.60% per year. The lowest was -71.40% per year. And the median was 3.65% per year.


Atara Biotherapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Atara Biotherapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Price-to-Free-Cash-Flow Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atara Biotherapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Atara Biotherapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Price-to-Free-Cash-Flow falls into.



Atara Biotherapeutics Price-to-Free-Cash-Flow Calculation

Atara Biotherapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.69/-1.831
=N/A

Atara Biotherapeutics's Share Price of today is $0.69.
Atara Biotherapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Atara Biotherapeutics  (NAS:ATRA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Atara Biotherapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Executives
Jill Henrich officer: EVP, Global Head RA & Quality 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren officer: SVP, CFO 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen officer: EVP, Chief Sci. & Tech Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi officer: EVP, Chief Medical Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard officer: EVP, Chief Technical Officer C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell officer: Chief Tech. Operations Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080